Form 4: Marimed CCO Ryan Crandall Exercises RSUs

Marimed's Chief Commercial Officer, Ryan Crandall, converted 54,000 Restricted Stock Units into common stock, with a portion withheld for tax obligations.

Summary

• Ryan Crandall, Chief Commercial Officer of MARIMED INC. (MRMD), reported changes in beneficial ownership.
• On December 8, 2025, Mr. Crandall acquired 54,000 shares of common stock through the conversion of Restricted Stock Units (RSUs).
• The RSUs converted to common stock on a one-for-one basis at a price of $0 per share.
• Concurrently, 15,850 shares of common stock were disposed of to satisfy tax withholding obligations related to the RSU vesting, at a price of $0.0824 per share.
• Following these transactions, Mr. Crandall beneficially owns 823,075 shares of common stock directly.
• The RSUs that vested were part of a grant made on June 8, 2023.
• Remaining RSUs from this grant are scheduled to vest on June 8, 2026.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the vesting of Restricted Stock Units and subsequent tax withholding. It does not contain information that significantly alters the company's financial outlook or operational status, thus maintaining a neutral sentiment.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates a planned compensation event for a key executive, aligning management's interests with shareholders.
• The executive's beneficial ownership remains substantial at 823,075 shares, demonstrating continued equity stake in the company.

Negatives

• A portion of the vested shares (15,850 shares) was sold to cover tax withholding obligations, which is a standard practice but reduces the executive's immediate share count.

Future Outlook

The remaining Restricted Stock Units from the June 8, 2023 grant are scheduled to vest on June 8, 2026, indicating future equity compensation events for the Chief Commercial Officer.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the vesting and conversion of Restricted Stock Units (RSUs) and subsequent tax withholding. Such transactions are common across publicly traded companies as part of executive compensation plans and do not typically signal a change in company strategy or performance.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and does not directly impact the company's operational performance or financial health. It reflects the ongoing alignment of executive incentives with shareholder value through equity ownership.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The remaining Restricted Stock Units from the June 8, 2023 grant are scheduled to vest on June 8, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units and the subsequent sale of shares to cover tax obligations. Such events are standard components of executive compensation and do not provide new fundamental information about Marimed's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing does not present new catalysts for either upward or downward revaluation.

Keywords

Marimed, MRMD, Ryan Crandall, Restricted Stock Units, RSU, Insider Transaction, Form 4, Beneficial Ownership, Chief Commercial Officer